Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PPARA | Q07869 | 2/20 | 0.67 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.57 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429541 | 0.88 | PLA2G4B (0.68) | PLA2G4BLMNATSHRALOX15 | |
| SCHEMBL13349839 | 0.87 | PLA2G4B (0.63) | PLA2G4BPPARAPPARGKMT2A | |
| SCHEMBL413254 | 0.86 | LMNA (0.81) | PLA2G4BLMNAPPARAPPARGTSHR | |
| SCHEMBL3166349 | 0.85 | LMNA (0.65) | PLA2G4BLMNAPPARAPPARGCYSLTR2 | |
| SCHEMBL15063356 | 0.84 | LMNA (0.74) | PLA2G4BLMNAPPARAPPARGALOX15 | |
| SCHEMBL8744429 | 0.84 | PLA2G4B (0.73) | PLA2G4BTSHR | |
| SCHEMBL4397448 | 0.84 | TSHR (0.63) | PLA2G4BTSHRCYSLTR2CYSLTR1KMT2A | |
| SCHEMBL3159400 | 0.83 | LMNA (0.63) | PLA2G4BLMNAPPARAPPARGCYSLTR2 | |
| SCHEMBL11842813 | 0.83 | PLA2G4B (0.76) | PLA2G4BTSHR | |
| SCHEMBL9163844 | 0.83 | PLA2G4B (0.76) | PLA2G4BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | PLA2G4B 1964/4885LMNA 4383/4885PPARA 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.